Benzer Pharmacy unveils MTM offering
It has been announced by Benzer Pharmacy, that the Tampa- Fla.-based chain will be addressing the demand for clinical solutions to supervise overprescribing patients. The company will be tackling this issue by providing medication therapy management, or MTM, to its customers.
“Medication therapy management is a patient-centric approach to bridge the gap between pharmacists and patients. By providing increased access to pharmacists, patients are able to take on a more active role in their wellness journey,” Alpesh Patel, president of Benzer Pharmacy, said.
The services will include pharmacotherapy consultation, progress check-ins, anticoagulation management, health and wellness programs, immunizations and medication therapy reviews, among others.
“Medication therapy management is a program that helps ensure the patient is adherent with their medications,” Jazz Harvey, CPhT at Benzer Pharmacy, said. “At Benzer Pharmacy an MTM Specialist works alongside pharmacists to ensure the systematic process of collecting patient-specific information, assessing medication therapies to identify medication-related problems, developing a prioritized list of medication-related problems, and creating a plan to resolve them.”
Benzer Pharmacy also will offer comprehensive medication review, or CMR, services to those enrolled in the MTM program. CMR is a systematic process of collecting patient-specific information, assessing medication therapies to identify medication-related problems, developing a prioritized list of medication-related problems, and creating a plan to resolve them with the patient, caregiver and/or prescriber, according to the Centers for Medicare and Medicaid Services.
Those enrolled in the MTM program will have the option to refuse or decline any individual services or disenroll from the service with the company’s CMR offering.
Perrigo names new CEO
Perrigo on Monday announced the appointment of Uwe Röhrhoff as CEO, effective Jan. 15, following the retirement of John Hendrickson.
"I look forward to working with Perrigo's experienced management team, who have been instrumental in positioning the company's consumer OTC and prescription pharmaceutical businesses to capitalize on current trends in the market," Röhrhoff said. "I have long admired Perrigo's operational excellence and its mission to deliver high-quality, affordable healthcare products that improve the lives of patients and families. I see great opportunity to leverage the company's unique asset base and to lead its talented employees to deliver enhanced value for shareholders. Perrigo's core values resonate with me deeply, and I look forward to leading this organization into its next stage of evolution."
"The board of directors is excited to announce the appointment of Uwe as president and CEO," stated Laurie Brlas Perrigo chairman. "Uwe brings a strong track record of operational excellence, strategic growth and healthcare supply chain management. As the CEO of Gerresheimer, a publicly-traded international manufacturer for the global pharmaceutical and healthcare industries, Uwe's transformative strategic vision and focus on operational excellence enhanced the company's leading market positions and created significant value for shareholders of approximately 225% in total shareholder return as CEO. We are confident that his leadership style and industry, financial and operational expertise are the right fit for Perrigo. We are grateful to John for his passionate leadership and contributions to the company over the past 28 years. John has been a trusted leader, a great colleague and a friend to many, and we value his continued guidance as Uwe transitions into his new role."
Röhrhoff has more than 25 years of experience with Gerresheimer, which generated approximately $1.7 billion in revenue in 2016. He began his career with Gerresheimer in 1991, steadily advancing within the organization to serve in a number of key leadership roles in Europe and North America.
Röhrhoff was appointed to build out the company's business in the United States (1996-1998) and head the American subsidiary Gerresheimer Glass (2001-2010). He served as an executive board member (2003-2017), responsible for two of the company's three business units, and CEO (2010-2017) of Gerresheimer until his retirement in August 2017.
Hendrickson will resign as CEO and board member on Jan. 15 and will remain with the company until March 15 to ensure a smooth and successful transition.